Algorae Pharmaceuticals Ltd (ASX:1AI) Share Price

Company Profile

Business description
Algorae Pharmaceuticals Ltd is a clinical-stage pharmaceutical company developing transformative solutions for under met medical needs in the community. The firm develops AlgoraeOS, a closed-loop platform, leveraging computational tools to generate novel insights in silico that are being developed to initiate or accelerate therapeutic programs. The products of the company comprise AI-116, a novel combination drug candidate of cannabidiol (CBD) and an off-patent pharmaceutical ingredient. The company is conceptualized to be a potential treatment for dementia, including Alzheimer’s disease, NTCELL is an alginate-coated capsule containing clusters of neonatal porcine choroid plexus cells. It also offers LP-003 Anti-obesity Drug and LC-002 migraine treatment.
Contact
525 Collins Street
Level 23, Rialto South Tower
MelbourneVIC3000
AUS
T: +61 422180317
https://www.algoraepharma.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
48

Recommended

The magnitude of growth at Broadcom continues to astound us.

William Kerwin, CFA | 10 September 2025

The banking major needs to prevent key product offerings from falling further behind the competition.

Nathan Zaia | 10 September 2025

A great fiscal 2025 but investors are ahead of themselves.

Mark Taylor | 08 September 2025

Index	Last price	Change	% Change
All Ordinaries	9,095.20	28.80	0.32%
CAC 40	7,761.32	11.93	0.15%
DAX 40	23,632.95	85.50	-0.36%
Dow JONES (US)	45,411.39	299.95	-0.66%
FTSE 100	9,225.39	17.14	-0.19%
HKSE	26,200.26	262.13	1.01%
NASDAQ	21,916.93	37.44	0.17%
Nikkei 225	43,837.67	378.38	0.87%
NZX 50 Index	13,276.24	22.51	0.17%
S&P 500	6,532.32	19.71	0.30%
S&P/ASX 200	8,830.40	40.00	0.46%
SSE Composite Index	3,812.22	4.93	0.13%